Tech Company Financing Transactions

Cour Pharmaceuticals Funding Round

Cour Pharmaceuticals closed a $50 million Series B investment round on 6/18/2026. Investors included Lumira Ventures, Roche Venture Fund and Alpha Wave Ventures.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

8025 Lamon Ave.
Skokie, IL 60077
USA

Phone

Undisclosed

Website

www.courpharma.com

Email Address

[email protected]

Overview

COUR Pharmaceuticals is developing ?rst-in-class therapies designed to reprogram the immune system to achieve antigen-speci?c tolerance for immune-mediated disease. COUR's platform of immune-modifying nanoparticles aims to treat the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

John Puisis

        

Chief Financial Officer

Brian Bock

        

VP - Finance

Nick Bortolotti

        

VP - General Counsel

Tracy Weiner

        

VP - Product Management

Michael Boyne

        

Browse more venture capital transactions:

Prev: 6/18/2026: BoolSi venture capital transaction
Next: 6/18/2026: El Dorado venture capital transaction

Share this article

Where The Data Comes From

We do our best to record all VC transactions involving tech companies. VC investment data records on this site come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary